Chardan Capital Reiterates Rating on CAMP $CAMP
Key Points
- Chardan Capital now rates CAMP4 THERAPEUTICS CORPORATION ($CAMP) "buy" with a $6.50 target.
- The Street's average $CAMP price target is $7.92 (Strong Buy).
- $CAMP last traded around $4.19.
Chardan Capital reiterated its rating on CAMP4 THERAPEUTICS CORPORATION ($CAMP) to a "buy" rating, with a price target of $6.50 in a recent research note.
CAMP4 THERAPEUTICS CORPORATION ($CAMP) Stock
CAMP4 THERAPEUTICS CORPORATION Earnings
Analysts Set New Price Targets
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.